

BELARUS

Number of new cases

46 402

Number of deaths

22 644

Number of prevalent cases (5-year)

137 534


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	4 395 009	5 037 795	9 432 804
Incidence*			
Number of new cancer cases	24 933	21 469	46 402
Age-standardized incidence rate	360.5	223.6	273.2
Risk of developing cancer before the age of 75 years (cum. risk %)	36.8	22.8	28.6
Top 3 leading cancers (ranked by cases)**	Prostate Lung Colorectum	Breast Colorectum Corpus uteri	Colorectum Breast Prostate
Mortality*			
Number of cancer deaths	13 564	9 080	22 644
Age-standardized mortality rate	192.7	79.4	123.5
Risk of dying from cancer before the age of 75 years (cum. risk %)	21.5	9.1	14.3
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Stomach	Colorectum Breast Stomach	Lung Colorectum Stomach
Prevalence*			
5-year prevalent cases	68 731	68 803	137 534



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	4 972	19.9%
2nd	Lung	4 006	16.1%
3rd	Colorectum	3 086	12.4%
4th	Stomach	1 725	6.9%
5th	Kidney	1 540	6.2%
-	Others	9 604	38.5%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	5 183	24.1%
2nd	Colorectum	3 074	14.3%
3rd	Corpus uteri	2 295	10.7%
4th	Stomach	1 079	5.0%
5th	Thyroid	890	4.1%
-	Others	8 948	41.7%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Colorectum	6 160	13.3%
2nd	Breast	5 183	11.2%
3rd	Prostate	4 972	10.7%
4th	Lung	4 599	9.9%
5th	Stomach	2 804	6.0%
-	Others	22 684	48.9%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Colorectum	6 160	1	13.3	4.2	2 970	2	13.1	1.8	18 952	200.9
Breast	5 183	2	11.2	6.4	1 384	4	6.1	1.6	20 252	402.0
Prostate	4 972	3	10.7	9.2	1 134	6	5.0	1.8	19 327	439.8
Lung	4 599	4	9.9	3.5	3 824	1	16.9	2.8	6 071	64.4
Stomach	2 804	5	6.0	2.0	2 125	3	9.4	1.4	4 172	44.2
Corpus uteri	2 295	6	4.9	3.0	472	15	2.1	0.52	8 830	175.3
Kidney	2 276	7	4.9	1.7	667	8	2.9	0.48	7 363	78.1
Bladder	1 464	8	3.2	1.0	437	16	1.9	0.26	4 886	51.8
Pancreas	1 354	9	2.9	0.90	1 237	5	5.5	0.83	1 301	13.8
Leukaemia	1 219	10	2.6	0.85	705	7	3.1	0.46	3 766	39.9
Thyroid	1 109	11	2.4	0.86	45	27	0.20	0.03	4 152	44.0
Melanoma	1 103	12	2.4	0.78	326	19	1.4	0.22	4 060	43.0
NHL	1 023	13	2.2	0.72	476	14	2.1	0.32	3 408	36.1
Lip, oral cavity	908	14	2.0	0.67	514	13	2.3	0.39	2 842	30.1
Ovary	746	15	1.6	1.0	546	10	2.4	0.63	2 384	47.3
Larynx	705	16	1.5	0.55	401	17	1.8	0.31	2 462	26.1
Cervix uteri	668	17	1.4	0.91	371	18	1.6	0.46	2 311	45.9
Brain CNS	651	18	1.4	0.51	534	11	2.4	0.42	2 686	28.5
Liver	607	19	1.3	0.42	548	9	2.4	0.39	766	8.1
Oesophagus	584	20	1.3	0.45	531	12	2.3	0.41	876	9.3
Oropharynx	478	21	1.0	0.38	289	20	1.3	0.23	1 523	16.2
Multiple myeloma	385	22	0.83	0.28	258	22	1.1	0.18	1 170	12.4
Hypopharynx	380	23	0.82	0.30	267	21	1.2	0.21	836	8.9
Hodgkin lymphoma	238	24	0.51	0.19	63	26	0.28	0.05	955	10.1
Vulva	169	25	0.36	0.15	84	24	0.37	0.06	487	9.7
Gallbladder	163	26	0.35	0.09	109	23	0.48	0.06	187	2.0
Testis	138	27	0.30	0.23	20	30	0.09	0.04	569	13.0
Salivary glands	121	28	0.26	0.09	66	25	0.29	0.04	411	4.4
Penis	60	29	0.13	0.10	18	31	0.08	0.03	202	4.6
Mesothelioma	45	30	0.10	0.03	39	28	0.17	0.02	65	0.69
Nasopharynx	30	31	0.07	0.02	25	29	0.11	0.02	96	1.0
Kaposi sarcoma	27	32	0.06	0.02	6	33	0.03	0.00	53	0.56
All cancers	46 402	-	-	28.6	22 644	-	-	14.3	137 534	-
All cancers excl. NMSC	45 019	-	-	28.1	22 529	-	-	14.3	132 955	-

Data source and methods

Incidence



Country-specific data source: [{"dt_list": "National cancer registry" }]
Method: National (or sub-national with coverage greater than 50%) rates projected to 2022

Mortality

Country-specific data source: National (WHO)
Method: Most recent rates from one source applied to 2022 population

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

